Skip to main content
logo
Polaryx Therapeutics, Inc. (PLYX)
NASDAQ: PLYX · Real-Time Price · USD
1.990
0.00 (0.00%)
At close: Jul 29, 2026, 4:00 PM EDT
2.019
+0.029 (1.45%)
After-hours: Jul 29, 2026, 5:26 PM EDT

Polaryx Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Net Income
-6.48-8.99-30.36-3.78
Stock-Based Compensation
0.744.732.43.24
Other Adjustments
--26-
Changes in Accounts Payable
0.80.4-0.4-0.05
Changes in Accrued Expenses
0.02-0.04--0
Changes in Other Operating Activities
-0.42-0.04-0.220.43
Operating Cash Flow
-5.3-3.94-2.57-0.17
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Short-Term Debt Issued
--0.070.13
Short-Term Debt Repaid
---0.19-
Net Short-Term Debt Issued (Repaid)
---0.130.13
Issuance of Common Stock
4.244.497.32-
Net Common Stock Issued (Repurchased)
4.244.497.32-
Other Financing Activities
--0.03--
Financing Cash Flow
4.224.477.190.13

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Net Cash Flow
-1.080.524.62-0.05

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-5.3-3.94-2.57-0.17
Free Cash Flow Growth
----
Free Cash Flow Per Share
-0.11-0.09-0.08-0.02
Levered Free Cash Flow
-6.08-8.67-31.11-3.28
Unlevered Free Cash Flow
-4.33-7.51-4.97-3.41
SEC Filings: 10-K · 10-Q